Skip to main content

Ulcerative Colitis clinical trials at UC Irvine

3 in progress, 1 open to eligible people

Showing trials for
  • Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

    open to eligible people ages 18-80

    The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.

    Irvine, California and other locations

  • An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

    Sorry, not currently recruiting here

    The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).

    Irvine, California and other locations

  • Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

    Sorry, in progress, not accepting new patients

    This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in the Phase II OLE study (GA27927 [NCT01461317]) or the Phase III studies (GA28948 [NCT02163759], GA28949 [NCT02171429], GA28950 [NCT02100696], GA29102 [NCT02165215], and GA29103 [NCT02136069]) were included. Participants from the Phase II OLE study or the Phase III studies who are not eligible or willing to receive etrolizumab in the OLE-SM study, and who have completed the 12-week safety follow-up period will be enrolled in Part 2. Part 1 of OLE-SM will continue for up to 9 years after the first participant is enrolled into the study. Following Part 1, participants will enter Part 2 for a period of 92 weeks.

    Orange, California and other locations

Last updated: